Humacyte Announces FDA Approval of SYMVESS (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma | Morningstar

Humacyte Announces FDA Approval of SYMVESS (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular
Read more...